Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis

Yong Chul Lee (Jeonju, Republic of Korea), Yong Chul Lee, So Ri Kim, Kyung Bae Lee, Hae Jin Park, Soon Ha Kim

Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Session: IPF: from pathogenesis to treatment I
Session type: Thematic Poster
Number: 783
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Yong Chul Lee (Jeonju, Republic of Korea), Yong Chul Lee, So Ri Kim, Kyung Bae Lee, Hae Jin Park, Soon Ha Kim. Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis. Eur Respir J 2016; 48: Suppl. 60, 783

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013


Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013


Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016

Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013

17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013


Olodaterol attenuates bleomycin induced lung fibrosis in mice
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016


New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015

Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015

Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016


Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013

Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats?
Source: International Congress 2016 – ILD pathogenesis
Year: 2016


17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016


PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013


Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013

Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016

PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013


Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015

Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013